Company Information

Company Profile

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medications for anxiety, depression and other central nervous system, or “CNS,” diseases and disorders where current treatments are inadequate to address high unmet need. Our CNS portfolio includes three differentiated CNS drug candidates, PH94B, PH10 and AV-101, each with a novel mechanism of action, an exceptional safety profile, and therapeutic potential for multiple indications.

Contact Information

Investor Relations
Mark A. McPartland
Vice President, Corporate Development
T: (650) 577-3606
markmcp@vistagen.com

Valter Pinto / Allison Soss
T: (212) 896-1254 / (212) 896-1267
VistaGen@KCSA.com

Company Info

Address:
343 Allerton Avenue
South San Francisco, CA 94080

Telephone:
(650) 577-3600

Fax:
(888) 482-2602

Industry Classifications

Sector:
Healthcare

Industry:
Pharmaceuticals

NAICS:
Pharmaceutical Preparation Manufacturing (325412)

SIC:
Pharmaceutical Preparations (2834)